Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

When asked about how his time in the private sector in the banking and pharmaceutical industries since leaving the Senate may ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

The expatriates' welfare ministry yesterday said outbound migrant workers have to be registered with Bureau of Manpower, Employment and Training (BMET) first to have access to the Surokkha app for ...

The American drugmaker was one of 17 companies US President Donald Trump called on last summer to lower prices, and among the ...

Striking a blow for China’s so-called vaccine diplomacy, state media have mocked the United States for calling attention to its donation of 80 vials of COVID-19 vaccines to Trinidad and Tobago.

JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.